Stocks Health care FTH
NASDAQ · Health careFaeth Therapeutics, Inc. (FTH)
It posted a net loss of $211.4M. In fiscal 2025 capital spending exceeded operating cash flow by $20.5M. At September 30, 2026 it held $14.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Faeth Therapeutics, Inc.
- Net worth
- Faeth Therapeutics, Inc. has a market value (market cap) of $327.7M at the latest share price, and shareholders' equity of $161.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $20.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Faeth Therapeutics, Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Faeth Therapeutics, Inc. does
Faeth Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FTH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$21.1M | -$16.72 | -$20.5M |
| 2024 | n/a | -$30.2M | -$24.01 | -$24.8M |
| 2023 | n/a | -$34.1M | -$24.41 | -$32.2M |
| 2022 | n/a | -$48.6M | -$31.61 | -$39.3M |
| 2021 | n/a | -$36.8M | -$26.61 | -$32.3M |
| 2021 | n/a | -$20.1M | -$250.70 | -$18.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Faeth Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Other event 8-K
- November 9, 2026
- November 3, 2026
- November 3, 2026
- November 3, 2026
- October 27, 2026
- September 17, 2026Executive or director change8-KFaeth Therapeutics appointed company co-founder Dr. Karen Vousden to its Board of Directors.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Faeth Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Parikh Anand KiranPresident and CEO, Director | Gave as a gift | 100,000 | - |
| October 30, 2026 | Parikh Anand KiranPresident and CEO, Director | Gave as a giftindirect | 100,000 | - |
| July 1, 2026 | Stephenson Brian CChief Financial Officer | Boughtindirect | 4,400 | $103K |
| July 1, 2026 | Stephenson Brian CChief Financial Officer | Boughtindirect | 600 | $14.5K |
| June 30, 2026 | Stephenson Brian CChief Financial Officer | Boughtindirect | 1,910 | $43.8K |
| June 30, 2026 | Stephenson Brian CChief Financial Officer | Boughtindirect | 1,638 | $39.1K |
| June 30, 2026 | Stephenson Brian CChief Financial Officer | Boughtindirect | 4,255 | $106.3K |
| June 29, 2026 | Stephenson Brian CChief Financial Officer | Boughtindirect | 831 | $19.4K |
Who owns FTH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| VK Services, LLC13G, passive with 5 related filers | 10.2% | August 14, 2026 |
| S2G Investments, LLC13G, passive | 9.99% | June 23, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 7.8% | June 23, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 45 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 2,020,103 | +1,985,554 |
| Avoro Capital Advisors LLC | 1,444,039 | new |
| Baker Bros. Advisors LP | 1,286,411 | new |
| Balyasny Asset Management L.P. | 1,042,198 | +1,025,993 |
| RA Capital Management, L.P. | 722,020 | new |
| Vivo Capital, LLC | 722,020 | 0 |
| Logos Global Management LP | 722,020 | +692,020 |
| Fairmount Funds Management LLC | 722,020 | new |
| Caligan Partners LP | 629,467 | +503,465 |
| B Group, Inc. | 610,169 | new |
| Trails Edge Capital Partners, LP | 515,335 | +390,335 |
| Franklin Resources Inc | 494,516 | +361,010 |
| Octagon Capital Advisors LP | 361,010 | new |
| ADAR1 Capital Management, LLC | 361,010 | new |
| Cormorant Asset Management, LP | 1,028,242 | +722,020 |
| Marshall Wace, Llp | 206,508 | +140,778 |
| Boxer Capital Management, LLC | 180,505 | new |
| Patient Square Capital LP | 175,050 | new |
| Alyeska Investment Group, L.P. | 144,404 | new |
| Affinity Asset Advisors, LLC | 144,404 | new |
Insiders
6 insiders reported holding 1,458,562 shares in total, about $18.5M at the last price.
| Holder | Shares |
|---|---|
| Parikh Anand KiranPresident and CEO, Director | 817,699100,000 held indirectly |
| Peyer James10% owner | 285,284155,142 held indirectly |
| Millennium Management LLC10% owner | 133,986133,986 held indirectly |
| Cambrian BioPharma Inc10% owner | 130,142 |
| Stephenson Brian CChief Financial Officer | 46,68846,688 held indirectly |
| Hahn Stephen M.Director | 44,763 |
Questions about FTH
What does Faeth Therapeutics, Inc. do?
Faeth Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as FTH. Its shares trade on NASDAQ under the ticker FTH.
What is Faeth Therapeutics, Inc.'s net worth?
Faeth Therapeutics, Inc. has a market value (market cap) of $327.7M at the latest share price, and shareholders' equity of $161.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Faeth Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $211.4M.
When did Faeth Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the other event from November 9, 2026.
When is Faeth Therapeutics, Inc.'s next earnings report?
Faeth Therapeutics, Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare FTH with
Follow FTH
Get an email when Faeth Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Faeth Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.